StreetInsider.com News Articles

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Mon, 26 Oct 2026 08:52:00 -0400

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and suppress overactive immune cells responsible for inflammatory and autoimmune conditions by inhibiting IL-2 and IL-15 signalling

Long-acting MDNA209 extended median survival by up to 4-fold in aggressive mouse models of acute graft-versus-host disease

TORONTO and HOUSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune diseases, today announced new preclinical data demonstrating potent CD122 blockade and suppression of overactive immune-cell activity with MDNA209,

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Mon, 26 Oct 2026 08:52:00 -0400

Long-acting MDNA209 extended median survival by up to 4-fold in aggressive mouse models of acute graft-versus-host disease

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Mon, 26 Oct 2026 08:52:00 -0400

Long-acting MDNA209 extended median survival by up to 4-fold in aggressive mouse models of acute graft-versus-host disease

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Mon, 26 Oct 2026 08:52:00 -0400

Long-acting MDNA209 extended median survival by up to 4-fold in aggressive mouse models of acute graft-versus-host disease

Medicenna to present preclinical data on MDNA209 at Paris conference

Thu, 22 Oct 2026 07:00:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced it will present preclinical data on its investigational compound MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference in Paris, France, running October 21–24, 2026.

The presentation, titled "MDNA209 is a High Affinity CD122 Clamp that Functions as an IL-2/IL-15 Super-antagonist for the Treatment of Autoimmune Diseases," is scheduled for October 23, 2026, from 4:30 to 5:00 PM CEST. Dr. Minh D. To will deliver the presentation.

MDNA209 is an engineered protein in preclinical development that Medicenna describes as a potential first-in-class cytokine-based CD122 superantagonist. The compound is designed to block CD122, the

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

Thu, 22 Oct 2026 07:00:00 -0400

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and simultaneously inhibit IL-2 and IL-15 signaling to modulate an overactive immune system

TORONTO and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune diseases, today announced that it will present new preclinical data on MDNA209, its potential first-in-class cytokine-based CD122 superantagonist, at The Promises of Treg and Interleukin-2 Therapies Conference, taking place October 21–24, 2026, in Paris, France.

The landscape of CD122 therapy (targeting the

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

Thu, 22 Oct 2026 07:00:00 -0400

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and simultaneously inhibit IL-2 and IL-15 signaling to modulate an overactive immune system

The landscape of CD122 therapy (targeting the

Medicenna to present MDNA11 trial data at SITC 2026 meeting

Mon, 05 Oct 2026 09:00:10 -0400

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF) announced that topline data from its Phase 1/2 ABILITY-1 clinical trial of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, according to a press release from the Toronto and Houston-based company.

The abstract was selected as one of the top 150 abstracts at the meeting. The oral presentation is scheduled for November 7, 2026, from 4:30 to 4:45 p.m. MST during Oral Session 3 at the Phoenix Convention Center in Phoenix, Arizona.

The presentation, designated Abstract Number 517, is titled "MDNA11 Demonstrates Clinical Activity as

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Mon, 05 Oct 2026 09:00:00 -0400

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

TORONTO and HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Mon, 05 Oct 2026 09:00:00 -0400

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Thu, 01 Oct 2026 19:00:00 -0400

TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”).

Medicenna is pleased to announce that all of the nominees listed in its management information circular dated August 19, 2026 (the “Circular”), were elected as directors. Each director was elected with greater than 97% of the votes cast for by shareholders

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Thu, 01 Oct 2026 19:00:00 -0400

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Thu, 24 Sep 2026 07:00:00 -0400

TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract evaluating survival outcomes with bizaxofusp (formerly MDNA55) in unresectable, IDH-wildtype recurrent glioblastoma (rGBM) has been selected for an oral presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026), taking place November 12-15, 2026, in Philadelphia.

The oral presentation will be delivered by Dr. Nicholas A. Butowski, MD, Professor of Neurological Surgery and Director of

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Thu, 24 Sep 2026 07:00:00 -0400

The oral presentation will be delivered by Dr. Nicholas A. Butowski, MD, Professor of Neurological Surgery and Director of

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 07:00:00 -0400

TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 28^th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

Details on the presentation are as follows:

Date: Wednesday, September 16^th, 2026
Time: 12:00

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 07:00:00 -0400

Details on the presentation are as follows:

Date: Wednesday, September 16^th, 2026
Time: 12:00

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

H.C. Wainwright Reiterates Buy Rating on Medicenna Therapeutics (MDNA)

Thu, 02 Jul 2026 06:44:42 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).

The analyst commented: "On June 26, 2026, Medicenna reported FY2026 results (fiscal year ended March 31, 2026) and provided a corporate update. The Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting beta-enhanced IL-2 superagonist (no IL-2Rα binding), is on track to complete enrollment in 3Q26, prioritizing select advanced tumor types (cutaneous melanoma, endometrial cancer, and MSI-H/dMMR and MSS/TMB-H cancers) with a focus on 2L/3L post-anti-PD-1 settings. Enrollment is also underway for its Phase 1b NEO-CYT study evaluating MDNA11 in neoadjuvant melanoma with interim

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for